Triple combination antibody therapies
US11225523B2 · kind B2 · utility
1Cited by
7References
11Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 1, 2018 |
| Grant date | Jan 18, 2022 |
| Priority date | — |
| Expiry date | Oct 19, 2039 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed to triple combination therapies with anti-TIGIT antibodies, anti-PVRIG antibodies, and checkpoint inhibitors, including anti-PD-1 or anti-PD-L1 antibodies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.